Financial Snapshot

Revenue
$10.01M
TTM
Gross Margin
Net Earnings
-$9.656M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1940.0%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$10.92M
Q3 2024
Cash
Q3 2024
P/E
-2.235
Nov 29, 2024 EST
Free Cash Flow
-$12.17M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $7.298M $6.071M $5.169M $12.63M $7.910M $153.0K $335.0K $835.0K $1.201M $352.0K $0.00 $0.00 $0.00
YoY Change 20.21% 17.45% -59.07% 59.67% 5069.93% -54.33% -59.88% -30.47% 241.19%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $7.298M $6.071M $5.169M $12.63M $7.910M $153.0K $335.0K $835.0K $1.201M $352.0K $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Selling, General & Admin $6.520M $6.778M $6.377M $6.890M $8.490M $7.520M $7.570M $8.020M $4.530M $1.736M $1.740M $270.0K $0.00
YoY Change -3.81% 6.29% -7.45% -18.85% 12.9% -0.66% -5.61% 77.04% 160.94% -0.23% 544.44%
% of Gross Profit
Research & Development $15.52M $18.24M $15.38M $15.61M $12.85M $12.97M $10.24M $10.15M $7.187M $6.590M $1.380M $260.0K $20.00K
YoY Change -14.92% 18.58% -1.46% 21.53% -0.93% 26.58% 0.9% 41.26% 9.06% 377.54% 430.77% 1200.0%
% of Gross Profit
Depreciation & Amortization $134.0K $162.0K $169.0K $220.0K $182.0K $231.0K $246.0K $250.0K $232.0K $342.0K $0.00 $0.00 $0.00
YoY Change -17.28% -4.14% -23.18% 20.88% -21.21% -6.1% -1.6% 7.76% -32.16%
% of Gross Profit
Operating Expenses $22.04M $25.02M $21.76M $22.50M $28.60M $20.55M $17.81M $25.70M $24.22M $9.428M $3.120M $520.0K $30.00K
YoY Change -11.91% 14.98% -3.29% -21.33% 39.16% 15.4% -30.7% 6.12% 156.88% 202.18% 500.0% 1633.33%
Operating Profit -$14.74M -$18.95M -$20.17M -$20.69M -$20.40M -$17.48M -$24.87M -$23.02M -$9.076M
YoY Change -22.2% -6.05% 1.43% 16.74% -29.72% 8.03% 153.61%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Interest Expense $867.0K $309.0K $7.000K $80.00K $300.0K $186.0K $643.0K $881.0K $953.0K $15.28M
YoY Change 180.58% 4314.29% -91.25% -73.33% 61.29% -71.07% -27.01% -7.56% -93.76%
% of Operating Profit
Other Income/Expense, Net $619.0K $111.0K -$11.00K -$9.530M $96.00K -$163.0K -$581.0K -$2.000K -$44.00K -$3.000K
YoY Change 457.66% -1109.09% -99.88% -10027.08% -158.9% -71.94% 28950.0% -95.45% 1366.67%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Pretax Income -$14.12M -$18.84M -$20.17M -$19.31M -$20.60M -$20.56M -$18.06M -$30.80M -$26.17M -$6.690M -$3.120M -$520.0K -$30.00K
YoY Change -25.03% -6.62% 4.46% -6.26% 0.19% 13.87% -41.38% 17.71% 291.14% 114.42% 500.0% 1633.33%
Income Tax $0.00 -$2.959M $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.12M -$18.84M -$20.17M -$19.31M -$20.60M -$20.56M -$18.06M -$27.84M -$26.17M -$24.14M -$3.120M -$520.0K -$30.00K
YoY Change -25.03% -6.62% 4.46% -6.24% 0.16% 13.88% -35.15% 6.41% 8.38% 673.85% 500.0% 1633.33%
Net Earnings / Revenue -193.49% -310.26% -390.23% -152.89% -260.38% -13439.87% -5389.85% -3334.49% -2178.77% -6859.09%
Basic Earnings Per Share -$3.87 -$5.46 -$8.63
Diluted Earnings Per Share -$3.87 -$5.46 -$7.447M -$671.7K -$1.231M -$4.978M -$9.309M -$18.81M -$32.31M -$35.21M -$18.35M -$3.059M -$176.5K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Cash & Short-Term Investments $19.17M $35.63M $53.84M $31.66M $23.44M $2.560M $3.550M $4.180M $18.90M $10.36M $15.57M $100.0K $0.00
YoY Change -46.19% -33.83% 70.06% 35.07% 815.63% -27.89% -15.07% -77.88% 82.43% -33.46% 15470.0%
Cash & Equivalents $19.17M $35.63M $53.84M $31.66M $23.44M $2.560M $3.550M $4.180M $18.90M $10.36M $15.57M $100.0K $0.00
Short-Term Investments
Other Short-Term Assets $742.0K $1.221M $871.0K $790.0K $780.0K $720.0K $700.0K $580.0K $1.560M $160.0K $0.00 $0.00 $0.00
YoY Change -39.23% 40.18% 10.25% 1.28% 8.33% 2.86% 20.69% -62.82% 875.0%
Inventory
Prepaid Expenses
Receivables $928.0K $1.298M $67.00K $80.00K $7.200M
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $20.84M $38.15M $54.78M $32.54M $31.42M $3.280M $4.250M $4.760M $20.46M $10.52M $15.57M $100.0K $0.00
YoY Change -45.36% -30.36% 68.34% 3.56% 857.93% -22.82% -10.71% -76.74% 94.49% -32.43% 15470.0%
Property, Plant & Equipment $11.47M $945.0K $2.414M $1.850M $900.0K $390.0K $610.0K $790.0K $690.0K $160.0K $0.00 $0.00 $0.00
YoY Change 1113.44% -60.85% 30.49% 105.56% 130.77% -36.07% -22.78% 14.49% 331.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.648M $1.861M $1.625M $200.0K $200.0K $200.0K $200.0K $200.0K $250.0K $0.00 $40.00K $0.00
YoY Change -11.45% 14.52% 712.5% 0.0% 0.0% 0.0% 0.0% -20.0% -100.0%
Total Long-Term Assets $13.12M $2.806M $4.039M $5.630M $4.680M $11.44M $11.73M $11.90M $24.41M $160.0K $10.00K $50.00K $0.00
YoY Change 367.39% -30.53% -28.26% 20.3% -59.09% -2.47% -1.43% -51.25% 15156.25% 1500.0% -80.0%
Total Assets $33.96M $40.95M $58.82M $38.17M $36.10M $14.72M $15.98M $16.66M $44.87M $10.68M $15.58M $150.0K $0.00
YoY Change
Accounts Payable $1.915M $1.188M $839.0K $930.0K $600.0K $1.180M $460.0K $750.0K $1.090M $0.00
YoY Change 61.2% 41.6% -9.78% 55.0% -49.15% 156.52% -38.67% -31.19%
Accrued Expenses $1.277M $2.495M $2.664M $3.160M $3.190M $1.700M $2.160M $1.320M $1.490M $640.0K $410.0K $100.0K $0.00
YoY Change -48.82% -6.34% -15.7% -0.94% 87.65% -21.3% 63.64% -11.41% 132.81% 56.1% 310.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.220M $2.590M $1.030M
YoY Change 24.32% 151.46%
Total Short-Term Liabilities $3.909M $5.022M $4.442M $8.250M $17.20M $2.880M $5.840M $4.650M $3.610M $640.0K $950.0K $100.0K $0.00
YoY Change -22.16% 13.06% -46.16% -52.03% 497.22% -50.68% 25.59% 28.81% 464.06% -32.63% 850.0%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $3.220M $5.690M $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% -43.41%
Other Long-Term Liabilities $12.05M $4.822M $6.926M $6.780M $7.880M $0.00 $0.00 $40.00K $10.00K $0.00
YoY Change 149.98% -30.38% 2.15% -13.96% -100.0% 300.0%
Total Long-Term Liabilities $12.05M $4.822M $6.926M $6.780M $7.880M $0.00 $0.00 $3.260M $5.700M $0.00 $0.00 $0.00 $0.00
YoY Change 149.98% -30.38% 2.15% -13.96% -100.0% -42.81%
Total Liabilities $15.96M $9.844M $11.37M $15.03M $25.08M $2.880M $5.840M $7.900M $12.27M $640.0K $950.0K $100.0K $0.00
YoY Change 62.16% -13.41% -24.36% -40.07% 770.83% -50.68% -26.08% -35.62% 1817.19% -32.63% 850.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Basic Shares Outstanding 3.652B shares 3.448M shares 2.709M shares
Diluted Shares Outstanding 3.652B shares 3.448B shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $21.585 Million

About Pulmatrix, Inc.

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts and currently employs 22 full-time employees. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

Industry: Pharmaceutical Preparations Peers: AGILE THERAPEUTICS INC AYTU BIOPHARMA, INC Barrel Energy Inc. Hoth Therapeutics, Inc. Jaguar Health, Inc. JOHNSON & JOHNSON VYNE Therapeutics Inc. Unrivaled Brands, Inc. WEED, INC. Virpax Pharmaceuticals, Inc.